# Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

> **NCT02213042** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Aromatase Inhibitors (AIs)

## Key facts

- **NCT ID:** NCT02213042
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-24
- **Primary completion:** 2020-06-04
- **Final completion:** 2020-06-04
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Primary analysis was completed in 2018 and continued minimal data collection from the one participant active in the study was not expected to add meaningful knowledge to the understanding of lapatinib
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213042, "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02213042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*